The Effect of Licopid and Bifid and Lactic Acid Bacteria Complex on Lysozyme Activity as the Factor of Nonspecific Immune Protection in Chronic Gastric and Duodenal Ulcer

The aim of the investigation is to study the effect of Licopid and bifid and lactic acid bacteria complex on Helicobacter pylori eradication and lysozyme activity as the factor of nonspecific immune protection in gastric and duodenal ulcer. Materials and methods. There were studied 30 patients suffering from Helicobacter associated gastric and duodenal ulcer, lysozyme activity was determined in 8 conditionally healthy individuals. There were used endoscopic, cytomorphological, and immunological (polymerase chain reaction, photonephelometric) techniques. To study the effect of immunomodulator and probiotic on eradication and nonspecific immune protection, there were determined H. pylori contamination and lysozyme activity of oropharyngeal secretion and gastric juice before and after the treatment. Results. The analysis of biopsy specimens and lysozyme biological tests revealed the use of immunomodulator (Licopid) and bifid and lactic acid bacteria complex combined with anti-Helicobacter pylori therapy increases H. pylori eradication and enhances lysozyme activity of saliva and gastric juice compared to data on quadroscheme. Conclusion. The administration of Licopid and bifid and lactic acid bacteria complex can be recommended in complex therapy of patients suffering from Helicobacter associated gastric and duodenal ulcers.